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Abstract
Tumor cells exhibit altered lipid metabolism compared with normal cells. Cell signaling kinases 
are important for regulating lipid synthesis and energy storage. How upstream kinases regulate 
lipid content, versus direct targeting of lipid-metabolizing enzymes, is currently unexplored. We 
evaluated intracellular lipid concentrations in prostate and breast tumor spheroids, treated with 
drugs directly inhibiting metabolic enzymes fatty acid synthase (FASN), acetyl-CoA carboxylase 
(ACC), diacylglyceride acyltransferase (DGAT), and pyruvate dehydrogenase kinase (PDHK), or 
cell signaling kinase enzymes PI3K, AKT, and mTOR with lipidomic analysis. We assessed 
whether baseline lipid profiles corresponded to inhibitors' effectiveness in modulating lipid 
profiles in three-dimensional (3D) growth and their relationship to therapeutic activity. Inhibitors 
against PI3K, AKT, and mTOR significantly inhibited MDA-MB-468 and PC3 cell growth in two-
dimensional (2D) and 3D spheroid growth, while moderately altering lipid content. Conversely, 
metabolism inhibitors against FASN and DGAT altered lipid content most effectively, while only 
moderately inhibiting growth compared with kinase inhibitors. The FASN and ACC inhibitors' 
effectiveness in MDA-MB-468, versus PC3, suggested the former depended more on synthesis, 
whereas the latter may salvage lipids. Although baseline lipid profiles did not predict growth 
effects, lipid changes on therapy matched the growth effects of FASN and DGAT inhibitors. 
Several phospholipids, including phosphatidylcholine, were also upregulated following treatment, 
possibly via the Kennedy pathway. As this promotes tumor growth, combination studies should 
include drugs targeting it. Two-dimensional drug screening may miss important metabolism 
inhibitors or underestimate their potency. Clinical studies should consider serial measurements of 
tumor lipids to prove target modulation. Pretherapy tumor classification by de novo lipid synthesis 
versus uptake may help demonstrate efficacy.
Introduction
In solid tumors, cancer cells often reside in a hypoxic and metabolically compromised 
environment where oxygen and nutrient delivery, and acid clearance are reduced. Cancer 
cells adapt metabolically in many ways to these conditions (1, 2), including changes in fatty 
acid (FA) metabolism. The substrate for de novo FA biosynthesis is cytoplasmic acetyl-CoA, 
which can be produced from glucose, glutamine, and acetate (3, 4). Glucose undergoes 
glycolysis to produce pyruvate, which enters the mitochondria and is converted to acetyl-
CoA by pyruvate dehydrogenase (PDH). This mitochondrial acetyl-CoA is converted to 
citrate by the enzyme citrate synthase (CS) and can be either further oxidized through the 
tricarboxylic acid cycle (TCA) or transported to the cytosol, where it is cleaved by ATP-
citrate lyase (ACLY) to produce oxaloacetate and acetyl-CoA, the precursor for FAs (Fig. 1).
To produce FAs, such as palmitic acid, acetyl-CoA is carboxylated to produce malonyl-CoA 
by Acetyl-CoA carboxylase (ACC), which is then condensed with acetyl-CoA to produce 
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FAs by fatty acid synthase (FASN). Three of the major enzymes involved in FA 
biosynthesis, ACLY, ACC, and FASN, have been implicated in malignant transformation (3, 
5-7). Many cancers, including breast and prostate cancer, show an increased expression of 
FASN, and this is associated with poor prognosis in various types of cancer (8-10). FAs are 
the substrates utilized to produce complex lipid species. For example, esterification of 
diacylglycerol (DG) with FAs, by diacylglyceride acyltransferase (DGAT), leads to the 
formation of triacylglycerides (TG), which is used for energy storage. This process occurs in 
the endoplasmic reticulum where TG are packaged into lipid droplets (LD), which has been 
shown to accumulate under hypoxic condition. LD is associated with higher tumor 
aggressiveness (11) and chemotherapy resistance (12), and protects cells from reoxygenation 
phase from ROS-induced cell death (13).
Intermediates of the FA pathway can also be converted into different phosphoglycerides, 
including phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine 
(PS), and phosphatidylinositol (PI), which build the major structural components of 
biological membranes (14, 15). Other phosphoglycerides, such as phosphatidic acid (PA), 
phosphatidylglycerol (PG), and cardiolipin (CL), constitute a relatively minor portion of the 
total cellular phosphoglycerides, and CL is restricted to the mitochondria where it mainly 
supports mitochondrial functions. Increased levels of phospholipid content have been shown 
to correlate with cell transformation and tumor progression (14, 16-18), indicating that the 
phospholipid synthesis rate increases with oncogenesis and tumor progression. Another class 
of lipids that are found in cell membranes includes sphingolipids such as Sphingomyelin 
(SM), which consist of a serine backbone as opposed to the glycerol backbone, and sterols 
such as cholesterol. Cholesterol acts to modulate the membrane fluidity and permeability via 
interacting with neighboring lipids, such as PC and SM. Cholesterol and sphingolipid 
metabolism have been shown to be deregulated in cancer (19, 20). Many lipids in plasma 
membrane and organelles affect cell signaling, the availability of intrinsic membrane 
proteins, membrane fluidity, and cell polarization (21).
Some of the metabolic enzymes are regulated by the hypoxia transcription factor-1α 
(Hif-1α) pathway and/or receptor tyrosine kinase (RTK)–mediated activation of PI3k/Akt 
and mTOR pathway through the activation of sterol regulatory element-binding proteins 
(SREBP; refs. 13, 22-24). SREBP upregulates the expression of stearoyl-CoA desaturase 
(SCD), fatty acid desaturase 1 (FADS1), FASN, ACC, ACCS2, ACLY, and solute carrier 
family 25 member 1 (SLC25A1; Fig. 1). Hypoxia can also inhibit PDH through the 
induction of its negative regulator pyruvate dehydrogenase kinase 1 (PDHK1) by Hif-1α 
(25-27). This decreases the oxidation of pyruvate to acetyl-CoA, increases the reduction of 
pyruvate to lactate, and reduces the synthesis of acetyl-CoA. Reduced acetyl-CoA levels 
present a dilemma for cancer cells that continue to proliferate under hypoxic conditions, 
with respect to FA synthesis, which is normally dependent on glucose-derived acetyl-CoA. 
Instead, hypoxic cancer cells utilize glutamine and acetate to generate Acetyl-CoA (refs. 3, 
4; Fig. 1).
These enzymes are therapeutic targets, and a key question is whether direct inhibitors of 
lipid metabolism would be a more effective strategy than broadly targeting upstream 
regulators. For this reason, with LC/MS-based lipidomics analysis, we analyzed and 
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compared the effects of inhibition of the PI3K/AKT/mTOR cell signaling pathway to cell 
metabolism inhibitors that target FASN, ACC, DGAT, and PDHK enzymes in prostate and 
breast cancer cell lines. This was performed under culture conditions relevant to those 
encountered within the tumor microenvironment in vivo, i.e., spheroid cultures that 
reproduce nutritional gradients and oxygen deprivation observed in tumors and could 
therefore enhance the effectiveness of drugs affecting lipid metabolism. The final aim was to 
elucidate lipid profile at baseline and after therapy, to assess if this was related to drug 
effectiveness and could identify other potential targets for synthetic lethality.
Materials and Methods
Cell lines
Cell lines were obtained from the London Research Institute (CRUK) cell services. The cell 
lines were authenticated using short tandem repeat profiling by CRUK and published in 
previous publications (3, 28). The PC3 cell line was grown in RPMI supplemented with 10% 
FCS (PAA Laboratories), 2 mmol/L L-glutamine, and penicillin/streptomycin. The MDA-
MB-468 cell lines were grown in DMEM/F12 with 10% FCS (PAA Laboratories), 2 mmol/L 
L-glutamine, and penicillin/streptomycin. Cells were maintained in a humidified incubator at 
5% CO2 and 37°C. For hypoxic exposure, cells were grown at 0.1% O2, 5% CO2, and 37° C. 
They were regularly checked for mycoplasma and validated.
Drugs
Drugs against metabolic enzymes FASN (AZ22), ACC (AZ52), DGAT (AZ17), and PDHK 
(AZ30), and cell signaling enzymes PI3K (AZ46), AKT (AZ28), and mTOR (AZ64) were 
provided by AstraZeneca (S.E. Critchlow, AstraZeneca) and dissolved in DMSO (Table 1 
for compound potency on recombinant enzymes, and compound structure in Supplementary 
Fig. S1). Concentrations used are indicated in the relevant figure legend, and controls were 
treated with 1% DMSO.
Two-dimensional drug viability assay
For two-dimensional (2D) growth, cells were plated in 96-well plates (2,000–5,000 cells per 
well). After 24 hours, media were replaced with drugs at different concentration or 1% 
DMSO alone as control. Cells were grown for 3 days in normoxic (20% O2) or hypoxic 
(0.1% O2) conditions. Cell proliferation was measured using the CyQUANT NF Cell 
Proliferation Assay Kit (Invitrogen—Life Technologies) following the manufacturer's 
instructions. Data and growth inhibition by 50% (GI50) calculation was carried out using 
GraphPad Prism 6 software using Nonlinear regression, log(inhibitor) vs. response – 
Variable slope calculation (GraphPad Software, Inc.).
Spheroid drug viability assay
For spheroid formation, cells were mixed with 2% Matrigel (Becton Dickinson) in culture 
medium and plated into 96-well ultralow attachment plates (Costar CLS7007), 10,000 cells 
per spheroid. Spheroid formation was initiated by centrifugation at 850 × g for 10 minutes, 
and cultures were incubated for the times indicated. Fresh growth medium, containing drug 
or 1% DMSO alone, was administered first after 48-hour growth and replaced every 48 
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hours. Spheroid size was determined at the times indicated using an inverted microscope 
(Axiovert 100M, Carl Zeiss) where spheroid area was calculated using ImageJ software 
(29). Spheroid area was used to calculate spheroid radius (r = √(A/π)), from which the 
diameter (d = 2r) and volume can be calculated (v = (4/3)π r3). Data and growth inhibition 
by 50% (GI50) calculation was carried out using GraphPad Prism 6 software using Nonlinear 
regression, log (inhibitor) vs. response – Variable slope calculation (GraphPad Software, 
Inc.).
Mass spectrometry
Twenty to 25 PC3 and MDA-MB-468 spheroids were treated for 4 days with the inhibitors, 
collected, and were shipped to Babraham Institute Lipidomics Facility on dry ice for lipid 
mass spectrometry analysis. Spheroid samples were resuspended in LC-MS grade water. 
Half of the suspension was extracted, derivatized prior to phosphoinositide UPLC-MS/MS 
analysis as previously described (30). The other half was used for Folch extraction and 
analysis of all the other lipids using LC-MS/MS as described previously (3). Lipids in drug-
treated spheroids were compared with 1% DMSO-treated control spheroids, and lipid 
differential abundance was calculated as were their carbon lengths and double-bond 
numbers. Data were normalized as ng of lipids per 106 total and viable cells. To count cells 
in spheroids, a sample of 5 spheroids was collected and tryps-inized. Cells were counted 
using SD100 Cellometer Counting Chamber slides (Nexcelcom) and Cellometer Auto x4 
Cell Counter (Nexcelcom). Data uploaded to Metabolights hosted by EBI can be seen 
athttps://www.ebi.ac.uk/metabolights/.
Statistical analysis and bioinformatics
Lipid abundance data were preprocessed using the R statistical program (v3.2.4). Total and 
viable cell population was used to normalize the cell lines. Data were transformed to log2 
scale for subsequent analysis. Statistical comparison between the treatment and control 
groups was performed using the paired t test, except for cases where valid abundances were 
only available for less than three samples, in which case only fold change was reported. 
Within the treatment groups, the presence of saturated, monounsaturated, and 
polyunsaturated lipid families was compared using ANOVA followed by the Tukey Honest 
Significant Differences (HSD) test for pair-wise comparisons. Comparison between 
saturated, monounsaturated, and polyunsaturated lipid families was performed using the 
paired t test. Analysis, heatmaps, and barplots were generated by the R statistical program 
(v3.2.4). For heatmaps and hierarchical clustering, unsupervised exploratory analysis of the 
metabolomics data (standardized by z-score scale), k-mean, was utilized to determine the 
optimal number of clusters.
Results
Lipidomic analysis of PC3 and MDA-MB-468 spheroids
We first generated extracts from spheroid cultures of prostate and breast cancer cells lines 
and subjected these to lipidomic analysis to analyze total amount and proportion of lipids in 
the two cell lines (Fig. 2A and B). This revealed that PC3 cells had significantly higher total 
lipid content than MDA-MB-468 cells (Fig. 2A). A total of 60,000 ng of lipid/106 cells and 
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26,000 ng of lipid/106 cells were detected in PC3 and MDA-MB-468 spheroids, 
respectively.
Three cell membrane phospholipids, PC, PI, and CL, were the most abundant lipid species 
detected in spheroids from both cell types (Fig. 2A and B). Other phospholipids detected 
included PE, PS, PG, and lyso-PC (LPC). Alkyl-phospholipids, alkyl-PC (aPC), alkyl-PE 
(aPE), and alkyl-LPC (aLPC), and PA and lyso-PA (LPA) were detected in smaller quantities 
in MDA-MB-468 and PC3 spheroids. PC3 spheroids had more phospholipids than MDA-
MB-468, with PC, aLPC, and PI being significantly higher (Fig. 2A).
SM was the most abundant sphingolipid (Fig. 2B), whereas ceramide (Cer), which is 
produced de novo from SM, was detected in smaller amounts. PC3 spheroids had more 
sphingolipids than MDA-MB-468, with SG and SM being significantly higher.
The most abundant neutral lipid detected was TG, followed by monoglyceride (MG) and DG 
(Fig. 2B). MG and DG are found in lower amounts in cells as they are intermediates in the 
catabolism or synthesis of TG. The amount of neutral lipids in both PC3 and MDA-MB-468 
was similar, but PC3 cells did significantly have more free fatty acid (FFA). Analysis of lipid 
proportion (Fig. 2A and B) reveals that lipid constituents were in similar proportions in the 
two cell lines, except for TG, MG, and FFA that were higher in proportion in MDA-MB-468 
than PC3.
Inhibition of monolayer and spheroid growth with kinase and metabolic enzyme inhibitors
We used inhibitors against the metabolic pathway enzymes PDHK, ACC, FASN, and DGAT, 
and the kinase enzymes PI3K, AKT, or mTOR on cells cultured as monolayers or as 
spheroids, and calculated the GI50 (Table 2). In monolayer cultures, after 3 days of exposure 
in normoxic or hypoxic conditions, all drugs, with the exception of the DGAT inhibitor, 
attenuated MDA-MB-468 and PC3 cell growth (Supplementary Fig. S2A and S2B; Table 2). 
The kinase inhibitors acting upon PI3K, AKT, or mTOR had the lowest GI50 for MDA-
MB-468 and PC3 cells, while the ACC inhibitor had a limited effect in inhibiting growth of 
both MDA-MB-468 and PC3 cells under hypoxic conditions (Table 2).
All drugs inhibited spheroid growth following 8 days of exposure for MDA-MB-468 
spheroids (Fig. 3A and B; Table 2) and 12 days for PC3 spheroids (Fig. 4A and B). As with 
monolayer cultures, a greater effect on growth was observed with kinase inhibitors acting on 
AKT, PI3K, and mTOR (Figs. 3 and 4; Supplementary Fig. S3; Table 2). As with 
monolayers, the metabolic inhibitors were less effective in inhibiting spheroid growth (Figs. 
3 and 4; Supplementary Fig. S3; Table 2). MDA-MB-468 spheroids were more sensitive to 
FASN and PDHK inhibitors (Fig. 3; Supplementary Fig. S3A), whereas PC3 spheroids were 
sensitive to FASN and ACC inhibitors (Fig. 4; Supplementary Fig. S3B). Unlike 2D growth, 
DGAT did inhibit PC3 spheroid growth, whereas MDA-MB-468 spheroids were more 
resistant to this inhibitor (Supplementary Fig. S3; Table 2).
Effects of metabolic and kinase inhibitors on cellular lipids
To establish the effect of inhibitors on cellular lipids, we used two different concentrations 
of inhibitors, and lipid changes were analyzed by trend (Supplementary Figs. S4-S6) and 
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significance (Fig. 5; Supplementary Fig. S7). Drug concentrations were selected based on 
data from previous experiments. Drugs that inhibited PI3K, AKT, and mTOR kinases altered 
levels of many lipid species in spheroids from both cell types (Supplementary Fig. S4), but 
only a small proportion of lipid species were significantly altered (Fig. 5; Supplementary 
Fig. S7; Table 3). In contrast, inhibitors against metabolic enzymes DGAT and FASN were 
more effective in changing lipid levels in both cell types (Supplementary Fig. S5) with many 
being significant (Fig. 5; Supplementary Fig. S7; Table 3).
Neutral lipids.—The PI3K inhibitor at 0.3 μmol/L and the AKT inhibitor at 3 μmol/L and 
0.3 μmol/L significantly reduced several TG species in MDA-MB-468 spheroids, whereas 
no significant changes were observed with the mTOR inhibitor (Fig. 5A). DG and MG 
concentrations were not significantly altered, but a trend in increasing levels was observed 
following AKT inhibition (Supplementary Fig. S4A), which suggests that targeting the 
PI3K/AKT pathway inhibits DGAT. In PC3 spheroids, the PI3K inhibitor at 0.3 and 0.1 
μmol/L, and the mTOR inhibitor at 1 μmol/L reduced several TG and DG species, whereas 
no significant changes in TG levels were seen with the AKT inhibitor (Fig. 5B), showing 
contrasting and reciprocal effects of the mTOR and AKT inhibitors between the cell lines.
The most significant changes in neutral lipids were observed following treatment with 
inhibitors against FASN and DGAT (Fig. 5; Supplementary Fig. S7). A trend and a 
significant reduction in total TG and several TG species were observed in MDA-MB-468 
spheroids following treatment with FASN and DGAT inhibitors (Supplementary Fig. S5A 
and S5B; Fig. 5; Supplementary Fig. S7A). FASN inhibition also significantly reduced 
levels of total DG and MG in MDA-MB-468 spheroids, confirming the role of FASN in FA 
synthesis, which is required to make MG, DG, and TG (Fig. 5A). In contrast, FASN 
inhibition did not significantly reduce TGs in PC3 spheroids, but a trend was observed 
(Supplementary Fig. S5A), whereas 100 μmol/L DGAT inhibitor in PC3 spheroids 
significantly reduced several TGs (Fig. 5B). It is possible that PC3 rely less on lipid 
synthesis than MDA-MB-468 and acquire FA via uptake.
No clear trend in lipid changes was observed following treatment with ACC and PDHK 
inhibition (Supplementary Fig. S6). However, inhibition of ACC (10 μmol/L) had a small 
and significant effect on lowering several TGs and DGs in MDA-MB-468 cells, but only 
affected 52:1 TG in PC3 spheroids (Fig. 5). The PDHK inhibitor treatment at 10 and 1 
μmol/L resulted in a significant increase in several TGs in MDA-MB-468 spheroids, but not 
in PC3 spheroids (Fig. 5).
FFAs.—Very few significant changes in FFA levels were observed. The levels of poly-
unsaturated 18:2 and 22:6 FFA were significantly increased in MDA-MB-468 spheroids 
following treatment with PI3K and FASN inhibitors (Fig. 5A). The FFA 22:6 was also 
significantly increased in MDA-MB-468 spheroids following treatment with 10 μmol/L 
PDHK inhibitor. In PC3 spheroids, FFA 20:1 significantly decreased following treatment 
with 1 μmol/L mTOR inhibitor, whereas the ACC inhibitor at 10 μmol/L significantly 
increased FFA 22:3 (Fig. 5B), and an increasing trend was observed following treatment 
with 100 μmol/L DGAT inhibitor (Supplementary Fig. S5B). Again, this may suggest that 
PC3 rely less on lipid synthesis than MDA-MB-468 and acquire FA via uptake.
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Phospholipids.—With the cell signaling inhibitors, phospholipids in PC3 spheroids were 
more sensitive to AKT and mTOR inhibition than MDA-MB-468 spheroids (Fig. 5A and B; 
Supplementary Fig. S4A and S4C). Levels of CL, PI, PS, aPE, PE, and PC were 
significantly increased following treatment with 3 μmol/L AKT inhibitor in PC3 spheroids, 
and an increasing trend was observed in many phospholipids in both PC3 and MDA-
MB-468 spheroids (Supplementary Fig. S4A). Contrasting effects were observed in MDA-
MB-468 and PC3 spheroids following mTOR inhibition, with many phospholipids showing 
a decreasing trend in PC3 spheroids, whereas levels increased in MDA-MB-468 spheroids 
(Supplementary Fig. S4C). No clear trend on phospholipid levels was observed following 
treatment with PI3K inhibitor (Supplementary Fig. S4B), but PI3K inhibitor did 
significantly decrease some PA, PI, PC, and aPC species, and significantly increase several 
PC, PI, PS, and CL in MDA-MB-468 spheroids (Fig. 5A). In PC3 spheroids, the PI3K 
inhibitor was less effective but significantly reduced the levels of some CL, PI, aPE, LPC, 
and PC species, whereas total LPA and some aPC and PC species were significantly 
increased (Fig. 5B).
Analysis of phospholipids following treatment with lipid metabolism inhibitors against 
DGAT and FASN revealed no clear trend (Supplementary Fig. S5), but did show that DGAT 
and FASN inhibitors were the most effective in significantly altering levels, with PC3 being 
more sensitive to DGAT inhibition, whereas MDA-MB-468 were more sensitive to FASN 
inhibition (Fig. 5A and B). This again may suggest that PC3 rely less on lipid synthesis than 
MDA-MB-468 and acquire FA via uptake.
In PC3 spheroids treated with 100 μmol/L DGAT inhibitor, many CL, PA, PI, PS, aPE, PE, 
and PC species and 28:0 aPC were significantly upregulated, suggesting increase in both the 
CDP-DG pathway and the Kennedy pathway, whereas LPC, aPC, and some PI, PS, and aPE 
species were significantly decreased (Fig. 5B). In contrast, fewer significant changes in 
phospholipid levels were observed in MDA-MB-468 spheroids treated with DGAT inhibitor, 
where 36.6 aPE, 34:0 PS, 36:0 PI, 30:0, 32:0 and 34:0 PA, and 34:0 PG were significantly 
reduced following treatment with 100 μmol/L DGAT (Fig. 5A).
MDA-MB-468 spheroids were more sensitive than PC3 spheroids to FASN inhibition. PA, 
PI, PS, PE, PG, and CL were significantly reduced following FASN inhibition, and this 
coincided with a reduced MDA-MB-468 spheroid growth (Fig. 5A). Some polyunsaturated 
PI and PC species were significantly upregulated in MDA-MB-468 spheroids, whereas 
shorter saturated PC (e.g., 26:0, 28:0, and 30:0) decreased following treatment (Fig. 5A). 
Increases in polyunsaturated PCs levels were also observed in PC3 spheroids treated with 1 
μmol/L FASN inhibitor (Fig. 5B). FASN inhibition in MDA-MB-468 spheroids significantly 
reduced total saturated PC, PI, and PE, whereas no changes were observed in total saturated 
phospholipids in PC3 spheroids (Supplementary Fig. S8). Unlike PC, some aPC species 
significantly decreased in MDA-MB-468 and PC3 spheroids following FASN inhibition.
Inhibition of ACC and PDHK resulted only in a small number of significant changes in 
phospholipids in MDA-MB-468 and PC3 spheroids (Fig. 5). However, an increasing trend in 
phospholipids was observed in MDA-MB-468 following treatment with 10 μmol/L ACC 
inhibitor (Supplementary Fig. S6A).
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Sphingolipids.—The levels of different sphingolipids were also significantly altered by 
PI3K, PDHK, ACC, and FASN inhibition in MDA-MB-468 spheroids and by PDHK, PI3K, 
and mTOR inhibition in PC3 spheroids, with the majority being downregulated. The PI3K 
inhibitor at 0.3 μmol/L significantly downregulated 26:1 SM, 14:0, 16:0 and 20:0 dhSM, and 
24:0 and 26:0 dhCer in MDA-MB-468 spheroids (Fig. 5A). Only 24:0 dhSM species were 
significantly downregulated in PC3 spheroids (Fig. 5B). The levels of 12:0 and 14:0 SM 
were significantly reduced in PC3 spheroids by the mTOR inhibitor (Fig. 5B).
Addition of the PDHK inhibitor at 10 μmol/L caused a reduction in 20:0 dhCer in MDA-
MB-468 spheroids and 24:0 dhSM in PC3 spheroids (Fig. 5A and B). The ACC inhibitor 
downregulated some dhCer species and upregulated 14:0 dhSM species in MDA-MB-468 
spheroids, whereas no change was observed in PC3 spheroids (Fig. 5A and B).
Finally, the FASN inhibitor at 10 μmol/L significantly reduced total Cer and several SM, 
shSM, and dhCER species, whereas in contrast, 14:0 dhSM was significantly upregulated in 
MDA-MB-468 spheroids (Fig. 5A). However, no changes in sphingolipids were seen in PC3 
spheroids after treatment with the FASN inhibitor.
Discussion
A key aim of the study was to asses if baseline lipid profiles were related to growth delay 
produced by agents inhibiting major pathways of lipid metabolism. The initial lipid profiles 
in the PC3 versus MDA-MB-468 spheroids differed significantly. PC3 cells had higher total 
lipid content and had a higher proportion of membrane lipids compared with TGs, whereas 
MDA-MB-468 had higher proportion of TGs compared with membrane lipids. Thus, the 
effects of specific inhibitors of key enzymes that can regulate these pathways might be 
predicted by the predominance of the substrates and products. PC3 were more sensitive to 
DGAT. TGs comprised 12% of lipids in MDA-MB-468 but only 3% in PC3. MG similarly 
were elevated in MDA-MB-468 (7%) versus PC3 (2.9%). Although no flux analysis was 
performed, the data suggest that there was much greater storage in MDA-MB-468, and great 
utilization or turnover in PC3, reflected in the increased sensitivity to DGAT in the latter cell 
line. Cancer cells, especially breast cancer, have larger number of LD containing TG in their 
cytoplasm than normal cells (31-33). LD role in cancer is only beginning to be explored, and 
recent evidence suggests that higher levels of LDs are associated with higher tumor 
aggressiveness (11) and chemotherapy resistance (12), and protect cells from reoxygenation 
phase from ROS-induced cell death (13). Reducing LD in cancer cells may help in cancer 
treatment by removing protective effects of LD.
In PC3 cells, there was a higher phospholipid proportion. Inhibition of ACC, which 
regulates the first and rate-limiting step in the biosynthesis of FAs, has been shown to 
change phospholipid composition, reducing PG and altering cell membrane properties (34), 
and thus might be expected to have a greater effect on cells with a higher proportion of 
phospholipids.
The in vitro results for metabolic inhibitors on purified enzyme assays were much more 
effective than on intact cells, in the nanomolar range in the former and micromolar in the 
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latter (Tables 1 and 2). This is most likely due to cellular uptake and excretion, as the tool 
compounds were selected for specificity and inhibitory potency. However, the 2D and 
threedimensional (3D) results are both in the micromolar range, and in many cases, the 
drugs were 5 or more fold more effective against 3D growth. Thus, it is unlikely that uptake 
is the main cause for differences between cell lines and drug activity. The data support the 
importance of analyzing 3D growth, particularly for drugs directly affecting metabolic 
pathways, which would allow metabolic gradients and exchanges to be targeted.
The inhibitor effects on lipids were studied only in 3D for the above reasons. A further key 
aim was to assess if the changes induced in lipid profiles were related to baseline levels or 
the antiproliferative effects. DGAT inhibitor did significantly reduce a greater range of 
neutral lipids in PC3 than MDA-MB-468, potentially correlating with growth-inhibitory 
effects and baseline profile.
For ACC inhibition, the overall effects on lipids were small and showed no selective effects 
on phospholipids in PC3 cells. In this case, there was no prediction based on effects on 
lipids, but it is possible that the cells depend on different isoforms of ACC, cytoplasmic 
ACC1, and mitochondrial ACC2 both inhibited by AZ52 (34). Inhibiting the latter would 
affect beta-oxidation as opposed to lipid synthesis and be unlikely to show major changes in 
lipids. Inhibition of ACC did show more lipid changes in MDA-MB-468 cells and spheroid 
growth. The difference in effects on lipids and growth may reflect greater reliance on 
synthesis in MDA-MB-468, whereas PC3 may adapt by upregulation of lipid transport and 
uptake, e.g., by FABP regulation (13). Studies have demonstrated that prostate cancer cells 
have low rate of glycolysis and glucose uptake, and tend to uptake FA (35). The preferential 
uptake of lipids over glucose in prostate cancer has previously been assessed for potential 
therapeutic targeting (35-37).
Most effective metabolic targeting drugs that altered lipid profiles in MDA-MB-468 and 
PC3 cells were inhibitors that target FASN and DGAT (Fig. 6). FASN inhibition was more 
effective on the growth of MDA-MB-468 cells and produced greater reduction in lipid 
profiles, particularly TG, DG, and MGs, with much less effects on PC3 lipids. The MDA-
MB-468 has lower total lipids, so baseline was not predictive. Again, the difference in 
effects on lipids and growth may reflect greater reliance on synthesis in MDA-MB-468. 
DGAT inhibition, PC3 growth more than MDA-MB-468 and produced greater and more 
significant TG reduction in the former cell line.
For PDHK inhibition, we observed little effect on lipid profile, and spheroid growth was 
moderately affected. This was unexpected, as hypoxia should render cancer cells more 
sensitive to this inhibitor, by reactivating Krebs cycle activity under adverse conditions.
Thus, for two of the drugs, against ACC and FASN, it appeared that if a cell line was more 
dependent on lipid synthesis, there would be change in lipids and growth on treatment, but if 
lipid uptake was more important, there would be no lipid change and growth. For three 
targets, the reduction in lipid profiles correlated with a reduction in growth (ACC, FASN, 
and DGAT).
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Whereas all the above discussion relates to 3D growth in normoxia, we conducted 2D 
growth experiments in normoxia and hypoxia. Overall, there was little change in drug 
sensitivity in hypoxia, showing that using hypoxia to try to replicate in vivo conditions was 
not sufficient to generate the sensitivity found in 3D growth. This supports the use of 3D 
models for metabolism inhibitors, where more severe hypoxia and gradients for many 
metabolites occur.
Although not novel, our results show that inhibitors of the kinases PI3K, AKT, and mTOR 
are about 10-fold more potent than lipid metabolism inhibitors in blocking the growth of 
cancer cells in spheroid cultures, likely due to multiple cellular processes they inhibit 
(38-40). Each of the signaling kinase inhibitors modified lipid profiles in both PC3 and 
MDA-MB-468 cancer cell lines. However, for these inhibitors, the effect on lipid 
composition did not correlate with their effect on cell growth. For example, the pan PI3K 
inhibitor was more active in changing lipid profiles in MDA-MB-468 than in PC3 cells, but 
was 7-fold less potent in reducing MDA-MB-468 spheroid growth when compared with PC3 
cells.
Both cells have a functional PI3K and a mutant PTEN and p53 (41, 42), and are sensitive to 
inhibitors against PI3K and AKT, but PC3 cells were more sensitive to pan PI3K inhibition. 
Similarly, the AKT inhibitor produced a stronger effect on lipid metabolism in PC3 cells 
compared with MDA-MB-468 cells. However, the drug effects on spheroid growth were 
equivalent in both cell types.
For mTOR inhibition, there were major effects on lipid profile in PC3 cells but only a 
minimal response in MDA-MB-468, showing that mTOR has different functions in these 
cells, yet the GI50 for this drug was similar.
Thus, for these signaling kinase inhibitors, the direction and extent of change in lipid 
profiles were not related to their growth effects. Our data show that, in spite of the 
importance of these kinases for lipid metabolism, their therapeutic efficacy is likely to be 
due to their effects on other targets (38-40).
Although inhibitors of lipid metabolism can prevent the formation of some lipid species, 
they can also increase the formation of others with potential protumorigenic properties. In 
our study, we observed that DGAT inhibition leads to increased levels of several 
phospholipids (e.g., PC, PE, PS, CL, and the majority of PI species), most likely due to the 
inhibition of the metabolic step converting DG into TG (Fig. 6). As DG is the main 
metabolic substrate for the synthesis of phospholipids via the Kennedy/CDP-DG pathway, 
inhibition of DGAT can enhance phospholipid synthesis. The most abundant phospholipid 
that increased following DGAT inhibition was PC, which is known to contribute to increased 
growth in cancer cells (14, 16-18). The second most abundant phospholipid that was 
increased following DGAT inhibition was PI, which is involved in lipid signaling, cell 
signaling, and membrane trafficking (30, 43). The third accumulating lipid was CL, which is 
located mainly on the inner membrane of mitochondria and activates enzymes involved in 
oxidative phosphorylation (44). PE and PS were detected at lower amounts but still 
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increased following DGAT inhibition. These lipids have key roles in metabolism and 
apoptosis (21, 45).
FASN inhibition was also associated with a relative increase of polyunsaturated FA, which 
could be attributed to enhanced FA uptake or the increased hydrolysis of TG, DG, and MG, 
thus increasing the pool of unsaturated and polyunsaturated FA, which can serve as substrate 
for the synthesis of polyunsaturated PC.
The clinical relevance of these data relates to screening and developing effective drugs 
targeting lipid metabolism, and the development of pharmacodynamic markers to select 
appropriate patients for clinical trial and prove the target has been inhibited in the tumor 
tissue. Thus, screening in 3D rather than 2D will be important, due to its more complex 
environment that is similar to a tumor environment, which will give a more relevant drug 
dose response. Baseline lipid profiles are unlikely to predict the effectiveness of the drugs, 
but a way to classify tumors which have a large component of lipid uptake versus de novo 
synthesis may be helpful. This could be done by PET imaging with agents that include 
acetate, choline and palmitate (46, 47). Most relevant would be serial analysis of biopsies to 
detect the changes in profiles on therapy and prove that dosage regimen at least modified the 
target.
Many of these drugs tested here reduced the levels of TG, found in LD, which may reduce 
tumor aggressiveness, chemotherapy resistance, and protection against ROS-induced cell 
death (11-13). With regards to upregulation of lipids on therapy, the Kennedy pathway has 
been extensively investigated as a drug target (14, 16-18, 48). Inhibition of choline kinase 
alpha (CKα), the first committed step to PC synthesis, by the selective small-molecule ICL-
CCIC-0019, suppressed growth of a panel of cancer cell lines and inhibited tumor xenograft 
growth in mice (48), and one CKα inhibitor has been used in phase I clinical trials against 
advanced solid tumors (http://clinicaltrials.gov/show/NCT01215864). Our data suggest that 
combination strategies including such drugs should be tested, as single modifiers alone are 
unlikely to be effective.
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Figure 1. 
Lipid biosynthesis in cancer cells. FAs are required by cells to build cell membrane as 
phospholipids and for energy storage as TG, which is stored in LDs and catabolized in the 
mitochondria through β-oxidation to provide energy. Lipids can be transported from 
extracellular source or synthesized by cells using glucose, glutamine, and acetate as carbon 
source. Cell signaling pathways can also increase lipid biosynthesis. Ligand binding to RTK, 
which activates PI3K phosphorylation of PIP2 to PIP3, activates AKT and mTOR pathway 
resulting in activation of the transcription factor SREBP. SREBP can upregulate citrate 
transporter SLC25A1 and lipid synthesis enzymes ACLY, ACSS2, ACC, FASN, and SCD. 
Hypoxia also plays a part in lipid biosynthesis, where Hif-1α upregulates glucose uptake, 
several enzymes in lipid biosynthesis, and reduces flux of glucose to acetyl-CoA through the 
mitochondria by upregulating PDHK1/4, kinase that inhibits PDH. Enzymes colored in 
yellow were those targeted with inhibitors. Metabolites are in square white boxes, enzymes 
are in oval boxes, transcription factors are in hexagonal boxes, and metabolic pathways are 
in bold and italics. Red arrows represent upregulation of expression by transcription factors.
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Figure 2. 
Lipid levels in MDA-MB-468 and PC3 spheroids. Mass spectrometry analysis of lipids as 
(A) amount, and (B) percentage in each cell type.
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Figure 3. 
MDA-MB-468 spheroid growth inhibition with inhibitors. Microscope images (A) and (B) 
growth curves of spheroids treated with inhibitors against metabolic enzymes PDHK, ACC, 
FASN, and DGAT, and kinases PI3K, AKT, and mTOR following 8 days of growth. 
Between 5 and 15 spheroids were measured per condition, and errors bars represent SD.
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Figure 4. 
PC3 spheroid growth inhibition with inhibitors. Microscope images (A) and (B) growth 
curves of spheroids treated with inhibitors against metabolic enzymes PDHK, ACC, FASN, 
and DGAT, and kinases PI3K, AKT, and mTOR following 12 days of growth. Between 5 
and 15 spheroids were measured per condition, and errors bars represent SD.
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Figure 5. 
Significant differential abundance analysis of lipids as a heat map. (A) MDA-MB-468 and 
(B) PC3 spheroids were treated for 4 days with inhibitors against metabolic enzymes PDHK, 
ACC, FASN, and DGAT, and kinases PI3K, AKT, and mTOR at two different 
concentrations. All lipids were compared against DMSO control, normalized to total cells. 
Only lipids that were differentially abundant (P < 0.05) following treatment by at least one 
drug (see dots in heat map) are represented. Side covariates indicate lipid families, and lipids 
within each family are sorted by name. The paired t test was used where three replicates 
were available. Only fold change is reported where two samples were available (P < 0.05 
and absolute log2FC > 1).
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Figure 6. 
Phospholipid and TG synthesis pathway. Phospholipids in cells can be synthesized via the 
CDP-DG and Kennedy pathway using PA and TG. Inhibitors against FASN and DGAT have 
an impact on both pathways. FASN inhibitor inhibits FA biosynthesis, whereas DGAT 
catalyzes the synthesis of TG from DG and Acyl-CoA. AGPAT, 1-acylglycerol-3-phosphate 
O-acyltransferase 1; CDS, cytidylyltransferase; CLS, Cardiolipin synthase; CPET, choline/ 
ethanolamine phophotransferase; CPT, choline phosphotransferase; GPAT1/3, glycerol-3-
phosphate acyltransferase 1/3; PAP, phosphatidic acid phosphatase; PEMT, 
phosphatidylethanolamine N-methyltransferase; PGPS, phosphatidylglycerolphosphate 
synthase; PIS, phosphatidylinositol synthase; PSD1, phosphatidylserine decarboxylase; PSS, 
phosphatidylserine synthase.
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